Protocol Ledger

NCT07184944 · Phase III · RECRUITING

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Interventional Phase III clinical trial protocol NCT07184944 sponsored by Sanofi in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-22 Enrollment: 751 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07184944
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)751 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07184944
Protocol FieldVerified Registry Value
NCT IdentifierNCT07184944
Consolidated Lead SponsorSanofi
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment751 participants (ESTIMATED)
Registered Start Date2026-01-22
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI